Sitagliptin

Sitagliptin is a DPP‑4 inhibitor with modest HbA1c reduction and cardiovascular neutrality; it has no demonstrated heart failure outcome benefit. DPP-4 inhibitors may in fact exacerbate heart failure symptoms through oedema worsening. This is not the best drug for Mr. Green.

Please go back and re-consider.